| 0.126 -0.004 (-3.08%) | 12-29 14:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.23 |
1-year : | 0.27 |
| Resists | First : | 0.2 |
Second : | 0.23 |
| Pivot price | 0.03 |
|||
| Supports | First : | 0.08 |
Second : | 0 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.03 |
| MA(100) : | 0.02 |
MA(250) : | 0.16  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.4 |
D(3) : | 70.8 |
| RSI | RSI(14): 89.9 |
|||
| 52-week | High : | 0.46 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ONCR ] has closed above the upper band by 3.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 801.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.2 - 0.2 | 0.2 - 0.2 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.13 | 0.13 - 0.13 |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 26 Jun 2023
Hilco Streambank Seeks Offers to Acquire Patent Portfolio of Biopharmaceutical Company Oncorus - PR Newswire
Mon, 12 Jun 2023
Oncorus liquidates a week after shedding workforce - Fierce Biotech
Mon, 05 Jun 2023
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat - Yahoo Finance
Wed, 30 Nov 2022
Oncorus lays off 15% of workforce, drops solid tumor prospect - Fierce Biotech
Wed, 30 Nov 2022
Oncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce - Yahoo Finance
Fri, 07 Oct 2022
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer - Nature.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 448 (K) |
| Shares Short P.Month | 164 (K) |
| EPS | -3.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -124.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0.14 |
| Forward Dividend | 0 |
| Dividend Yield | 111.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|